How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/tsh-suppression-in-thyrotropin-dependent-well-differentiated-thyroid-cancer-adjunct-to-radioiodine-therapy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Levoxyl	Levothyroxine Sodium	Pfizer Inc.	Thyroid hormone replacement	Thyroid receptor proteins attached to DNA

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 1 drug in TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy:

Cite this brief

Drug Landscape (2026). TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tsh-suppression-in-thyrotropin-dependent-well-differentiated-thyroid-cancer-adjunct-to-radioiodine-therapy. Accessed 2026-06-10.

TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing